The increasing global appeal of Chinese firms’ novel therapies has propelled the country’s rise as a biomedical powerhouse, but China has yet to produce a drug to rival all-time best-selling Western blockbusters in sales. Beijing has set ambitious new five-year targets to boost its global presence, including at least five products with annual global sales surpassing US$1 billion by 2030. The goal is achievable, according to some analysts. Jefferies’ head of Asia healthcare research Cui Cui noted...
Read full article